A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Phase of Trial: Phase III
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Nivolumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 9DX
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 23 Oct 2018 Trial design data from this trial was presented at the 43rd European Society for Medical Oncology Congress.
- 10 Apr 2018 Planned End Date changed from 2 May 2025 to 7 Jun 2025.
- 10 Apr 2018 Planned primary completion date changed from 10 Apr 2022 to 17 Apr 2022.